Méhnyakrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 493 450 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 6 602 445 EUR· until 2029. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spanyolország· EU contribution 3 613 288 EUR· until 2028. máj.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Izrael· EU contribution 1 996 250 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norvégia· EU contribution 7 984 441 EUR· until 2027. aug.· 6 countries

5 of 6 running projects, newest first. Listed amounts together: 23,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Frissítve: 2026. jún. 4.

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Epidemiological characteristics of cervical cancer in Asian populations and risk factor inference based on Mendelian randomization.

  Medicine (Baltimore), 2026. okt.

• Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs.

  Medicine (Baltimore), 2026. szept.

• Causal effects of blood and urinary biomarkers on cancer risk: A Mendelian randomization study.

  J Int Med Res, 2026. júl.

• Bidirectional mendelian randomization identifies plasma proteins associated with cervical cancer risk.

  J Egypt Natl Canc Inst, 2026. júl.

• Cervical cancer mortality trends and inequities, 1999 to 2023: Joinpoint and spatial analyses integrated with two-sample Mendelian randomization.

  Medicine (Baltimore), 2026. máj.

• Absence of causal association between CD40-CD40L signaling and cervical cancer risk: A Mendelian randomization study.

  Medicine (Baltimore), 2026. máj.

• Immune Cells and Risk of Cervical Cancer: Evidence from a Mendelian Randomization Study.

  Clin Lab, 2026. ápr.

• The causal effect of cytokine cycling levels on the risk of cervical cancer: A bidirectional 2-sample Mendelian randomization study.

  Medicine (Baltimore), 2026. febr.

• Heavy metal exposure and cancer risk: Findings from a Mendelian randomization study.

  Toxicol Lett, 2026. febr.

• Investigating the relationship between taste perception of artificial sweeteners and cancer risk.

  Public Health Nutr, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.